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PSTATE-OF-THE-ART PAPER
Cardiovascular Protection Using Beta-Blockers
A Critical Review of the Evidence
Sripal Bangalore, MD, MHA,* Franz H. Messerli, MD,* John B. Kostis, MD,† Carl J. Pepine, MD‡
New York, New York; New Brunswick, New Jersey; and Gainesville, Florida
For more than 3 decades, beta-blockers have been widely used in the treatment of hypertension and are still
recommended as first-line agents by national and international guidelines. Recent meta-analyses indicate that,
in patients with uncomplicated hypertension, compared with other antihypertensive agents, first-line therapy with
beta-blockers was associated with an increased risk of stroke, especially in the elderly cohort with no benefit for the
end points of all-cause mortality, cardiovascular morbidity, and mortality. In this review, we critically analyze the evi-
dence supporting the use of beta-blockers in patients with hypertension and evaluate evidence for its role in other
indications. The review of the currently available literature shows that in patients with uncomplicated hypertension,
there is a paucity of data or absence of evidence to support use of beta-blockers as monotherapy or as first-line
agents. Given the increased risk of stroke, their “pseudo-antihypertensive” efficacy (failure to lower central aortic pres-
sure), lack of effect on regression of target end organ effects like left ventricular hypertrophy and endothelial dysfunc-
tion, and numerous adverse effects, the risk benefit ratio for beta-blockers is not acceptable for this indication. How-
ever, beta-blockers remain very efficacious agents for the treatment of heart failure, certain types of arrhythmia,
hypertropic obstructive cardiomyopathy, and in patients with prior myocardial infarction. (J Am Coll Cardiol 2007;
50:563–72) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.060I
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wn November 14, 2005, the New York Times reported
hat beta-blockers (atenolol) were the fourth most-
rescribed drug in the U.S., with 44 million prescriptions
early (1). Clearly, most of these prescriptions were for
ypertension and, during the past decade, national and
nternational guidelines have promoted beta-blockers to
e used on an equal footing with thiazide diuretics,
alcium antagonists, or renin angiotensin aldosterone
ystem (RAAS) blockers for initial therapy of hyperten-
ion (2– 4). According to authoritative sources who
rafted these guidelines, this preferred status was supposedly
ased on evidence documenting reduction in morbidity and
ortality with beta-blockers in hypertension. A closer look at
he available evidence has cast serious doubt on efficacy and
afety of beta-blockers for hypertensive cardiovascular disease.
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007, accepted April 30, 2007.n a recent editorial, Beevers (5) notes that many national
uideline committees should rethink their stand on beta-
lockers as reasonable first-line medications for treatment of
ypertension. As a consequence, headlines suggesting the end
f the beta-blocker era have suddenly appeared in the medical
iterature (5). Before we throw out the baby with the bathing
ater, it seems reasonable to critically analyze the evidence.
ow strong are the data on which the widespread use of
eta-blockers in cardiovascular disease is based?
eta-Blockers in Hypertension
or more than 3 decades, beta-blockers have been widely
sed in the treatment of hypertension and are still recom-
ended as first-line agents by national and international
uidelines (2,3). However, ever since the Veterans Admin-
stration study in the 1970s (6), multiple, prospective
andomized trials have documented that diuretic-based
ntihypertensive therapy reduces risk of stroke and, to a
esser extent, the risk of myocardial infarction and cardio-
ascular morbidity and mortality. However, the data are
uch less convincing for beta-blockers (7).
ffects on morbidity and mortality. It is somewhat ironic
hat after 3 decades of using beta-blockers for hypertension,
o study has shown that their monotherapeutic use has
educed morbidity or mortality in hypertensive patients even
hen compared with the use of placebo.
In some of the early trials like the British Medicalesearch Council study in the elderly, beta-blocker mono-
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but whenever a beta-blocker was
added to diuretics, the benefits of
the antihypertensive therapy dis-
tinctly diminished (8). Thus, pa-
tients who received the combina-
tion of beta-blockers and diuretics
fared consistently worse than those
on diuretics alone, but they did
somewhat better than those re-
ceiving beta-blockers alone (8,9).
Even in the more recent trials
like the ASCOT-BPLA (Anglo-
Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering
Arm) study of 19,257 patients
with hypertension and at least 3
other coronary risk factors but no
linically overt coronary artery disease, atenolol-based treat-
ent resulted in a 14% greater risk of coronary events and
3% greater risk of stroke when compared with an
mlodipine-based regimen (10).
Recent meta-analyses have shown that beta-blockers do
ot provide benefit for the end points of all-cause mortality
nd myocardial infarction even when compared with pla-
ebo, both in the elderly and in the younger cohort
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
CI  confidence interval
HR  hazard ratio
JNC  Joint National
Committee
LVH  left ventricular
hypertrophy
MI  myocardial infarction
NNH  number needed to
harm
RAAS  renin angiotensin
aldosterone system
verview of Major Meta-Analyses of Randomized Controlled Trials o
Table 1 Overview of Major Meta-Analyses of Randomized Contr
Meta-Analysis Parameter No. of Trials
vs. placebo
Cochrane, 2007 (18) Overall 4
Bradley et al., 2006 (12) Overall 4
Khan et al., 2006 (14) Younger 2
Khan et al., 2006 (14) Elderly 5
Lindholm et al., 2005 (15) Overall 7
Carlberg et al., 2004 (13)
(atenolol)
Overall 4
vs. other antihypertensive agents
Khan et al., 2006 (14) Younger 5
Khan et al., 2006 (14) Elderly 7
Lindholm et al., 2005 (15) Overall 13
Carlberg et al., 2004 (13)
(atenolol)
Overall 5
vs. diuretics
Cochrane, 2007 (18) Overall 4
Bradley et al., 2006 (12) Overall 5
Psaty et al., 2003 (16) Overall Network
vs. calcium antagonists
Cochrane, 2007 (18) Overall 4
Bradley et al., 2006 (12) Overall 4
BPLTTC, 2003* (17) Overall 9
vs. RAAS blockers
Cochrane, 2007 (18) Overall 3
Bradley et al., 2006 (12) Overall 3
BPLTTC, 2003 (17) Overall 9umbers represent hazard ratio (95% confidence interval).
BPLTTC  Blood Pressure Lowering Treatment Trialists’ Collaboration; RAAS  renin angiotensin aldosTable 1). Pooled analysis report that beta-blockers reduce the
isk of stroke by 16% to 22% when compared with placebo.
owever, this risk reduction is suboptimal compared with 38%
eduction for the same degree of blood pressure reduction
bserved with the use of other antihypertensive agents (11).
hen compared with other antihypertensive agents (12–18),
eta-blockers provide no benefit for the end points of
ll-cause mortality, cardiovascular mortality, and myocardial
nfarction, with a 16% to 30% increased risk of stroke (Table
). This was the case when all beta-blockers were analyzed
ogether and when atenolol was analyzed separately as a
ubgroup (15). Other meta-analyses since then have shown
imilar results with 24% and 30% greater risk of stroke
ompared with calcium antagonists and RAAS blockers,
espectively (12), with the risk being greater in the elderly
atients compared to younger patients (14). We (7) had
imilarly documented, nearly a decade earlier, that although
lood pressure was lowered with beta-blockers, these drugs
ere ineffective in preventing coronary artery disease, car-
iovascular events, and all-cause mortality (odds ratios 1.01,
.98, and 1.05, respectively) Our meta-analysis showed that
iuretic therapy was superior to beta-blockers with regard to
ll outcomes (fatal and nonfatal strokes, cardiovascular
vents, and all-cause mortality) (7).
here did we go wrong? Given this state-of-the-art
aper, one may appropriately inquire about the evidence on
ta-Blockers in Patients With Hypertension
Trials of Beta-Blockers in Patients With Hypertension
Mortality Myocardial Infarction Stroke
0.99 (0.88–1.11) 0.93 (0.81–1.07) 0.80 (0.66–0.96)
0.99 (0.88–1.11) 0.93 (0.81–1.07) 0.80 (0.66–0.96)
0.94 (0.79–1.10) 0.85 (0.71–1.03) 0.84 (0.65–1.10)
0.91 (0.74–1.12) 0.98 (0.83–1.16) 0.78 (0.63–0.98)
0.95 (0.86–1.04) 0.93 (0.83–1.05) 0.81 (0.71–0.93)
1.01 (0.89–1.15) 0.99 (0.83–1.19) 0.85 (0.72–1.01)
0.97 (0.83–1.14) 0.97 (0.86–1.10) 0.99 (0.67–1.44)
1.05 (0.99–1.11) 1.06 (0.94–1.20) 1.18 (1.07–1.30)
1.03 (0.99–1.08) 1.02 (0.93–1.12) 1.16 (1.04–1.30)
1.13 (0.97–1.33) 1.04 (0.89–1.20) 1.30 (1.12–1.50)
1.04 (0.91–1.19) 1.12 (0.82–1.54) 1.17 (0.65–2.09)
1.04 (0.91–1.19) 1.12 (0.82–1.54) 1.17 (0.65–2.09)
1.01 (0.93–1.10) 1.15 (0.97–1.35) 1.11 (0.94–1.31)
1.07 (1.00–1.14) 1.05 (0.96–1.15) 1.24 (1.11–1.40)
1.07 (1.00–1.14) 1.05 (0.96–1.15) 1.24 (1.11–1.40)
1.01 (0.96–1.05) 0.99 (0.93–1.06) 1.07 (1.00–1.16)
1.10 (0.98–1.24) 0.90 (0.76–1.06) 1.30 (1.11–1.53)
1.08 (0.95–1.23) 0.90 (0.76–1.06) 1.30 (1.11–1.53)
1.00 (0.95–1.05) 1.02 (0.95–1.10) 0.92 (0.85–1.00)f Be
olledterone system.
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August 14, 2007:563–72 Beta-Blockers in Cardiovascular Diseasehich the seventh report of the Joint National Committee
n prevention, detection, evaluation, and treatment of high
lood pressure (JNC 7) is based (3). It appears that the
uidelines were based mostly on trials like the STOP-2
Swedish Trial in Old Patients with hypertension-2) trial
19), the CONVINCE (Controlled ONset Verapamil
Nvestigation of Cardiovascular Endpoints) trial (20), the
ORDIL (Nordic Diltiazem) trial (21), the CAPPP
Captopril Prevention Project) trial (22), and most of all the
eta-analysis by Psaty et al. (23) published in 1997.
lthough in some of these trials patients were started on a
eta-blocker, more than two-thirds ended up on a combi-
ation of a beta-blocker with a diuretic, and no effort was
ade to separately analyze the morbidity and mortality
ffects of the beta-blocker, the diuretic, or the combination
f the two. We (24) had earlier suggested that it would be
rroneous to conclude from the results of these mixed trials
hat there was cardiovascular morbidity and mortality ben-
fit of beta-blockers. To illustrate the inappropriate use of
ncluding these studies as beta-blocker studies, we used an
nalogy model of the effects of gin and tonic on hepatic
irrhosis. One would hardly conclude that the tonic water
aused cirrhosis based on a study in which two-thirds of
atients were on gin and tonic and one-third on tonic water
lone, and no attempt had been made to separately assess
he effects (24).
To further illustrate the “dilution” effect of these trials, in
he meta-analysis by Lindholm et al. (15), in the studies
omparing beta-blockers to placebo, beta-blockers resulted
n a 19% reduction in stroke. However, when a sensitivity
nalysis was performed using only mixed beta-blocker/
iuretics studies versus placebo, the beta-blocker arm sud-
enly became more efficacious, with a 45% reduction in the
isk of stroke. Similarly, in the comparison of beta-blockers
ith other antihypertensive agents, a sensitivity analysis of
nly the mixed beta-blocker/diuretics studies failed to show
he 16% increased risk of stroke observed when all studies
ere included (15). It therefore appears that most of the
eneficial effects/nonharmful effects of these trials may be
he result of the diuretics and hence these studies should not
e used as evidence to suggest the beneficial effect of
eta-blockers.
ffects on blood pressure. Beta-blockers reduce blood
ressure compared with placebo. However, compared with
ther antihypertensive agents, the blood pressure-lowering
fficacy of beta-blockers is suboptimal (18). In the STOP-1
rial, blood pressure control was only half as effective in the
eta-blocker arm when compared with patients on a diuretic
25). Even in more recent trials like the LIFE (Losartan
ntervention for Endpoint Reduction in Hypertension) trial
26), blood pressure control was achieved in less than 50% of
atients assigned to the beta-blocker group, and less than
0% of patients remained on beta-blocker monotherapy. In
he ASCOT-BPLA trial, amlodipine-based treatment re-
ulted in a 1.7 mm Hg mean lower systolic pressure and 2.0
m Hg mean lower diastolic pressure, associated with a t4% lower risk of coronary events and 23% lower risk of
troke compared with atenolol-based treatment (10). In an
nalysis of 10 trials involving 16,164 elderly hypertensive
atients assigned to beta-blocker or diuretics, hypertension
as controlled in 66% of patients assigned to diuretics
onotherapy but was controlled in less than one-third of
atients on beta-blocker monotherapy (7).
seudo-antihypertensive efficacy. Beta-blockers are not
nly less efficacious at reducing peripheral blood pressure
ut also have a lesser effect on perhaps the more important
entral aortic pressure when compared with RAAS blockers,
iuretics, and calcium antagonists (27,28). In the CAFE
Conduit Artery Functional Endpoint) study (29), for the
ame peripheral blood pressure, a 4.3 mm Hg greater central
ortic systolic blood pressure and 3.0 mm Hg greater central
ortic pulse pressure was noted with atenolol based treat-
ent compared with the amlodipine-based treatment (29).
he study results also strongly suggest that the central aortic
ystolic blood pressure may be more predictive of cardiovas-
ular events, such as stroke and myocardial infarction, than
he traditional peripheral (brachial) blood pressure measure-
ents. Given this discrepancy between cuff and central
ortic pressure, the antihypertensive efficacy of beta-blockers
an be best described as a “pseudo antihypertensive” efficacy.
eta-blockers: side effects. Beta-blockers often are not
ell tolerated, and the compliance rate with these medica-
ions are dismal. In a meta-analyses of randomized con-
rolled trials, the risk of treatment withdrawal was 80% and
1% greater with beta-blockers compared with diuretics and
AAS blockers, respectively (12).
ew-onset diabetes mellitus. Since the 1960s, the meta-
olic side effects of beta-blockers have been widely studied.
eta-blockers have been shown to increase insulin resistance
nd predispose patients to diabetes. In a “network meta-
nalysis” of 22 clinical trials with 143,153 participants who
id not have diabetes at randomization, the risk of new-
nset diabetes was most pronounced with diuretics and
eta-blockers, more so than with placebo or other classes of
ntihypertensive agents, implying a negative metabolic ef-
ect of these medications (30).
Whether this new-onset diabetes induced by beta-
lockers has deleterious consequences is debatable. After a
edian of 6 years, the risk of cardiovascular events with
ew-onset diabetes was found to be similar to the risk in
atients with established diabetes and hypertension at base-
ine (31). Similarly, in the 18-year follow-up of the MRFIT
Multiple Risk Factor Intervention Trial), patients who had
eveloped diabetes during treatment had greater mortality
ates than those without diabetes (32). Alderman et al. (33),
n a follow-up of 6,886 hypertensive patients, found a
ignificant greater incidence of cardiovascular events in
ndividuals with in-treatment blood glucose levels of 139.5
g/dl or greater. Similarly, in a population-based cohort
tudy of 1,860 men followed up for 17.4 years, increased
lood glucose during treatment for hypertension (mainly by
hiazides and beta-blockers) was an independent risk factor
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Beta-Blockers in Cardiovascular Disease August 14, 2007:563–72or myocardial infarction (31). However, only in one study
o far, SHEP (Systolic Hypertension in the Elderly Pro-
ram), patients with diabetes at baseline had worse prog-
osis (adjusted hazard ratio [HR] 1.66, 95% confidence
nterval [CI] 1.41 to 1.95), patients with new-onset diabetes
hile on placebo had worse prognosis (adjusted HR 1.56,
5% CI 1.12 to 2.18), but patients with new-onset diabetes
hile receiving chlorthalidone had no excess cardiovascular
orbidity or mortality (adjusted HR 1.04, 95% CI 0.74 to
.46) after a follow-up of 14.3 years (34), leading some
nvestigators to conclude that new-onset diabetes caused by
hese medications might not be harmful.
Given the data from previous studies showing detri-
ental effects of new-onset diabetes, the long-term
therogenic potential of diabetes, whether primary or
econdary (to medications), cannot and should not be
gnored. Nevertheless, the economic consequences of
anagement of a chronic condition like diabetes and its
ong-term micro- and macrovascular complications
dded on to an asymptomatic and chronic condition like
ypertension would be enormous.
Potential mechanisms by which beta-blockers may con-
ribute to development of diabetes include weight gain,
ttenuation of the beta-receptor–mediated release of insulin
rom pancreatic beta cells (35), and decreased bloodflow
hrough the microcirculation in skeletal-muscle tissue, lead-
ng to decreased insulin sensitivity (36). The usefulness of
eta-blockers in patients at risk for diabetes (like those with
dvanced age, family history of diabetes, impaired glucose
olerance, elevated fasting glucose levels, obesity, and met-
bolic syndrome) is thus questionable.
However, in the GEMINI (Glycemic Effects in Diabetes
ellitus Carvedilol-Metoprolol Comparison in Hyperten-
ives) trial (35), treatment of diabetics with metoprolol
esulted in an increase in hemoglobin A1c whereas treat-
ent with carvedilol (a newer nonselective beta-blocker) did
ot, attesting to the fact that not all beta-blockers are
reated equal.
ffects on left ventricular hypertrophy (LVH) regression.
eft ventricular hypertrophy is a strong predictor of cardio-
ascular mortality and morbidity and its regression lowers
he risk, independent of blood pressure lowering effect (37).
n patients with hypertension, medications that regress
VH are therefore desirable. In the LIFE study, antihyper-
ensive treatment with losartan-based therapy resulted in
reater LVH regression than conventional atenolol-based
herapy (26). In a meta-analysis of 104 studies comparing
arious antihypertension strategies on LVH regression,
eta-blocker based therapy produced the least LVH regres-
ion compared with RAAS blockers, calcium antagonists,
nd diuretics (38). Beta-blockers, unlike RAAS blockers, do
ot decrease collagen content in the myocardium and hence
re not efficacious in LVH regression (39). The usefulness of
eta-blockers in patients with LVH is therefore questionable.
ascular effects. Hypertension stems from and results intructural and functional changes in the resistance vessels. vedications that improve endothelial function can there-
ore not only improve blood pressure control but also result
n substantial reduction in the cardiovascular end points of
troke and myocardial infarction. Beta-blockers have no
ffect on resistance blood vessels and endothelial function
ompared with other antihypertensive agents. In a prospec-
ive study of 19 untreated hypertensive patients randomized
o beta-blocker (atenolol) or calcium antagonist (amlodip-
ne), after 1 year of treatment, for the same blood pressure
ontrol, amlodipine resulted in correction of altered resis-
ance artery structure (on gluteal resistance vessels) and
ended to improve endothelial function, whereas similar
ood control of blood pressure with the beta-blocker did not
40). Furthermore, in another study, switching the medica-
ion from beta-blocker to the AT1 receptor antagonist
rbesartan resulted in correction of previously persistently
ltered vascular structure and endothelial dysfunction sug-
esting a structural and endothelial protective effect of AT1
eceptor antagonists (41). Improvement in endothelial func-
ion also has been demonstrated with other antihypertensive
gents like RAAS blockers (41,42). This effect on endothe-
ial function is thus independent of blood pressure control
nd seems to be an intrinsic property of these antihyperten-
ive agents (calcium antagonists/RAAS blockers). There-
ore, conceivably, the lack of cardioprotective effects of
eta-blockers in patients with essential hypertension maybe
ue to its failure to improve endothelial function and LVH.
eight gain. All hypertension management guidelines
ecommend weight loss and/or avoidance of medications
hat cause weight gain in obese hypertensive patients.
eta-blocker use, however, has been associated with small-
ut-systematic weight gain. In the few hypertension studies
hat reported weight status, beta-blocker use resulted in a
eight gain by as much as 1.2 kg (43). The weight gain
econdary to beta-blockers has been attributed to its effect
n decreasing metabolic activity by as much as 10% and also
n other effects on energy metabolism (43). Compared with
atients who maintain the same weight or lose weight,
atients who gain weight have a 2- to 3-fold greater risk of
eveloping diabetes (44). The usefulness of beta-blockers in
bese patients or patients with risk factors for diabetes is
hus questionable. In the GEMINI trial (45), patients on
etoprolol had a significant weight gain, but patients on
arvedilol did not, again attesting the fact that not all
eta-blockers are the same.
eta-blockers and exercise endurance. Exercise endur-
nce in a healthy person depends, in part, on a properly
unctioning sympathetic nervous system. Beta-blockers, by
ntagonizing this effect, may hamper exercise capacity. In
act, studies conducted half a century earlier have shown
hat surgical sympathetic denervation of the heart hinders
xercise performance in dogs (46). Epstein et al. (47)
bserved that propranolol in healthy volunteers reduced the
xercise endurance by 40% along with significant reduction
n heart rate, cardiac output, mean arterial pressure, left
entricular minute work, and central venous pressure. The
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August 14, 2007:563–72 Beta-Blockers in Cardiovascular Diseaseesults were similar in patients with heart disease and those
ith hypertension (48). Many other studies since have
hown a clear reduction in exercise endurance in young
ealthy test subjects and trained sportsmen. In sharp con-
rast, in patients with coronary artery disease, an improve-
ent in exercise tolerance with beta-blocker therapy has
een shown (49). This discrepancy between the 2 groups
as been attributed to differing behavior of the cardiovas-
ular system in health and in disease states.
The mechanism of reduced exercise tolerance in subjects
n a beta-blocker is in part secondary to hemodynamic
ffects (i.e., decrease in heart rate, cardiac output, mean
rterial pressure) and also due to its effect on glucose and
ipid metabolism. The usefulness of beta-blockers in young/
hysically active patients is thus questionable.
thers. Beta-blockers as a class have many undesirable
dverse effects, including drowsiness, lethargy, sleep distur-
ance, visual hallucinations, depression, blurring of vision,
reams/nightmares, pulmonary side effects such as increased
irway resistance in asthmatics, and peripheral vascular side
ffects such as cold extremities, Raynaud’s phenomenon,
rectile, and orgasmic dysfunction. The Medical Research
ouncil study allows us to calculate that for every myocar-
ial infarction or stroke prevented, 3 patients treated with
tenolol withdrew from the study secondary to impotence
nd another 7 withdrew because of fatigue (50). For an
symptomatic disorder such as mild hypertension, this
isk/benefit ratio is hardly an acceptable one.
isk/benefit ratio. Compared with other antihypertensive
gents, the number needed to harm (NNH) for beta-
lockers based on meta-analysis by Lindholm et al. (15) is
,500 patients, (i.e., treatment of 2,500 patients with
eta-blockers for 1 year results in 1 excess stroke). However,
hen only nonmixed beta-blockers/diuretic studies are con-
idered, the results are dismal for beta-blockers with NNH
f 909 patients/year of treatment. These data are worse
hen patients are treated with atenolol, with NNH of 714
atients/year of treatment. Using the same dataset, the
NH for elderly patients is 625 patients/year of treatment
after excluding the mixed beta-blocker/diuretic studies).
iven that 52 million patients have hypertension, beta-
locker therapy could potentially result in about 208,000
eedless strokes per year compared with other antihyper-
ensive agents. As always, the NNH should be weighed
gainst the potential benefits. However, because no study to
ate has shown the beneficial effects of beta-blockers for
ll-cause mortality, cardiovascular morbidity, and mortality
hen used as monotherapy for hypertension, their use for
his indication clearly violates the principle of primum non
ocere.
oint National Committee. Beta-blockers along with di-
retics were regarded as the preferred first line of treatment
rom 1984 to 1997 (JNC III to VI), although there was a
onsistent paucity or even absence of data to show the
eneficial effects of beta-blockers as first-line agents for
ypertension. The JNC VII recommends beta-blockers for ecompelling” indications on an equal basis with calcium
ntagonists, RAAS blockers (3). However, in patients with
compelling” indication for beta-blocker, it is unknown if
he beneficial effect of beta-blockers is secondary to its blood
ressure-lowering effects. Should the beta-blocker be used
oth for hypertension and the compelling indication
two-for-one “twofer”)? Although the twofer certainly is
ttractive from a pharmacoeconomic point of view, there
s no evidence that such an approach is efficacious or safe.
e therefore suggest in such a patient to use a beta-
locker for the compelling indication and to use a drug
hat has been shown to reduce morbidity and mortality
or hypertension (51).
hronic heart failure. Beta-blockers traditionally were
onsidered contraindicated in patients with heart failure
ecause of their initial transient negative inotropic effects.
owever, many studies have consistently shown a substan-
ial reduction in the rate of mortality (30%) and morbidity
ith the use of beta-blocker therapy, as well as an improve-
ent in symptoms and the patient’s well-being (52–54).
reatment of 15 to 43 patients with heart failure prevents 1
eath and, thus, beta-blockers are very effective in patients
ith heart failure (Fig. 1). Multiple meta-analyses have
choed this observation, showing mortality benefit in the
verall cohort (55,56), in the elderly or the young (57), in
en or women (58), in diabetics (59) or nondiabetics (60),
n patients with ejection fraction 25% or 25% (61), and
n patients on or not on background RAAS blocker therapy
62) (Fig. 2). Present American College of Cardiology/
merican Heart Association (ACC/AHA) guidelines
ightly recommend beta-blockers in patients with systolic
eart failure (63).
The reason for the difference in the efficacy of beta-
lockers in these 2 conditions are that, in patients with heart
ailure, the adrenergic system is activated (initially as a
ompensatory mechanism) with up-regulation of adrenergic
eceptors on the myocardium which over a long run results
n myocardial remodeling and fibrosis. Beta-blockers prob-
bly act to protect the heart from these harmful effects of
orepinephrine and epinephrine. Consequently, beta-
lockers have been, are, and will remain a cornerstone for
he treatment of heart failure. However, hypertension in the
lderly is characterized by decreased cardiac output, heart
ate, elevated systemic vascular resistance, decreased arterial
ompliance, and decreased beta-adrenergic responsiveness
nd, hence, beta-blockers are not effective in this subgroup
f patients.
oronary artery disease. The ACC/AHA committee rec-
mmends beta-blockers as the first-line therapy for chronic
table angina (64) based on 2 pieces of evidence: first, the
vidence of improved mortality with beta-blockers in post-
yocardial infarction (MI) patients, and, second, by extrap-
lation from the supposed effects of these agents in hyper-
ension, where the guidelines believe that beta-blockers
educe mortality. The first statement is reasonable, but
xtrapolating this evidence to patients with stable angina but
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o support the fact that beta-blockers used as monotherapy
r as first-line agents for hypertension have no mortality
enefits and increase the risk for stroke. Opie (65) recently
uggested that, in patients with stable angina and no prior
I, a calcium antagonist may be as beneficial without the
dverse effects of insulin resistance, weight gain, decreased
xercise tolerance, and sexual dysfunction associated with
eta-blockers. In patients with stable angina, when com-
ared with beta-blockers, long-acting calcium channel
lockers were noninferior for the end points of death/
yocardial infarction, frequency of anginal episodes, or
itroglycerine usage (66) and, hence, may be an acceptable
lternative.
Figure 1 Number Needed to Treat in Major Randomized
Controlled Trials of Beta-Blockers for Heart Failure
Treatment of 15 to 43 patients with heart failure prevents 1 death and, thus,
beta-blockers are very effective in patients with heart failure. CAPRICORN 
CArvedilol Post infaRction SurvIval COntRol in left ventricular dysfunctioN;
CIBIS  Cardiac Insufficiency Bisoprolol Study; COPERNICUS  CarvedilOl
ProspEctive RaNdomIzed CUmulative Survival Trial; MERIT-HF  MEtoprolol
CR/XL Randomized Intervention Trial in chronic Heart Failure.
Figure 2 Overview of Major Meta-Analyses of Randomized Cont
In patients with heart failure, beta-blockers are efficacious agents for the preventio
angiotensin receptor blockers; BB  beta-blocker; CI  confidence interval; HR 
Association.cute coronary syndromes. In the MIAMI (Metoprolol
n Acute Myocardial Infarction) study, early initiation of
ntravenous beta-blockade with metoprolol resulted in a
3% trend toward decreased mortality compared with pla-
ebo (67). Patients in the beta-blocker arm had lower
ncidence of ventricular and supra ventricular arrhythmias
67). In the ISIS-1 (International Study of Infarct Survival)
rial, early initiation of intravenous beta-blockade resulted in
15% trend toward decreased vascular mortality compared
ith placebo (68). The TIMI (Thrombolysis In Myocardial
nfarction)-2B study also demonstrated superiority of early
ntravenous beta-blocker therapy for patients with acute
T-segment elevation MI (69). However, not all studies
ave consistently demonstrated benefit of early intravenous
eta-blocker therapy: in the GUSTO (Global Utilization of
treptokinase and Tissue Plasminogen Activator for
ccluded Coronary Arteries) trial, early beta-blockade re-
ulted in a 30% increased risk of death, with a greater
ncidence of heart failure, shock, and pacemaker use (70). In
he recently concluded COMMIT (ClOpidogrel and Meto-
rolol in Myocardial Infarction) trial, early beta-blocker
herapy in acute MI reduced the risks of reinfarction and
entricular fibrillation but increased the risk of cardiogenic
hock by 30%, especially during the first day or so after
dmission (71). The risk of cardiogenic shock was greatest
n patients 70 years, in those with systolic blood pressure
120 mm Hg, heart rate 110 beats/min, and those
resenting with Killip III heart failure (71). Acute beta-
lockade should therefore be deferred in patients with acute
oronary syndrome until hemodynamic stability is achieved.
urther studies are needed to appropriately evaluate the role
f intravenous beta-blockers in patients with acute MI.
Trials of Beta-Blockers in Patients With Heart Failure
ardiovascular events. ACEi  angiotensin-converting enzyme inhibitors; ARBs 
ratio; LVEF  left ventricular ejection fraction; NYHA  New York Heartrolled
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August 14, 2007:563–72 Beta-Blockers in Cardiovascular Diseaseost-MI. Since it was first reported in 1965 that admin-
stration of propranolol after acute MI reduced mortality,
here is now increasing evidence that beta-blockers reduce
ortality in patients with prior MI, coming both from
eta-analyses of randomized trials (72) and from observa-
ional studies (73). These studies have shown that beta-
lockers reduce mortality by approximately 23% in prospec-
ive trials and up to 40% in observational studies (72,73).
reatment of 84 patients for 1 year prevents 1 death, and
reatment of 107 patients with beta-blockers for 1 year
voids 1 nonfatal reinfarction (74) and the benefit is
tronger with long-term use rather than the short term. The
umber needed to treat to achieve mortality reduction is
uch fewer for beta-blockers when compared with anti-
latelet agents or statins use after MI (74). The evidence for
eta-blockers in post-MI patient is thus strong, and patients
hould not be denied the benefits from beta-blockade where
nd when appropriate. However, most of these trials were
erformed in the era of medical management of MI, and it
s largely unknown whether the benefits hold true in the era
f reperfusion, RAAS blockers, statins, and aspirin.
Furthermore, beta-blockers often are not well tolerated,
nd their ability to control blood pressure, particularly in
lderly patients, is limited. In an analysis of 55,315 patients
ho survived an acute MI and were prescribed a beta-
locker, a RAAS blocker, and a statin, 74% of patients were
till receiving a RAAS blocker, 82% a statin, but only 58%
beta-blocker after 5 years of follow-up (75).
Alternative treatment strategies are therefore needed to
mprove compliance. In an recent analysis of the INVEST
International Verapamil-SR Trandolapril) study, we
howed that, in patients with prior MI, a heart rate-
owering calcium antagonists-based strategy (verapamil-SR)
as equivalent to a beta-blocker (atenolol)-based strategy
or the primary outcome (composite of all-cause mortality,
yocardial infarction, and stroke; HR 0.94, 95% CI 0.83 to
.06) with a trend toward 29% reduction in the risk of
onfatal stroke (HR 0.71, 95% CI 0.49 to 1.01) in the group
n Verapamil-SR when compared with the group on
eta-blockers (76).
erioperative beta-blockers. Perioperative beta-blockers
uring noncardiac surgery have been shown to be useful in
reventing postoperative cardiac complications. The mech-
nisms by which beta-blockers exert their perioperative
ardioprotective effect are multifactorial. Beta-blockers de-
rease myocardial oxygen demand by reduction of heart rate
nd myocardial contractility and reduce adrenergic activity
esulting in reduced levels of free fatty acid thereby causing
shift in the myocardial metabolism towards glucose
ptake.
In a meta-analysis of 1,077 patients, perioperative beta-
locker therapy was associated with a 56% reduction in the
isk of perioperative MI and 67% reduction in the risk of
erioperative MI or cardiac death when compared with
lacebo (77). Treatment of 32 patients with beta-blocker is
ssociated with 1 less perioperative MI (77), and the benefit Hs greater in patients undergoing high-risk surgery. Conse-
uently, the ACC/AHA guidelines on perioperative cardio-
ascular evaluation for noncardiac surgery recommends
eta-blockers in those already on therapy or who are
ndergoing vascular surgery and have ischemia on preoper-
tive testing (Class I) and for those undergoing vascular
urgery or intermediate or high-risk nonvascular surgery
ith high risk for coronary disease or those with established
isease (Class II) (78).
However, in the recently concluded MaVS (Metoprolol
n Vascular Surgery) trial, which had a sample size greater
han twice that of any study used by the guideline commit-
ee to make the recommendations, metoprolol was not
ffective in reducing the 30-day and 6-month postoperative
ardiac event rates when compared with placebo (79).
imilarly, in the DIPOM (Diabetic Postoperative Mortality
nd Morbidity) trial, metoprolol treatment before noncar-
iac surgery was not associated with decreased cardiac
vents rates when compared with placebo (80). Other large
andomized trials have similarly failed to show a cardiovas-
ular benefit of beta-blockade in patients undergoing non-
ardiac surgery (80).
ypertropic obstructive cardiomyopathy. Beta-blockers
re also efficacious in patients with hypertropic obstructive
ardiomyopathy, both for the reduction of symptoms and
reventing sudden cardiac death (81). However, in patients
ith mild or moderate hypertropic cardiomyopathy, treat-
ent with beta-blocker (nadolol) resulted in a greater
ecrease in peak exercise work load compared with a
erapamil strategy (82).
ther indications. Beta-blockers have been shown to reduce
achycardia and arrhythmias of everyday stress in pilots under-
oing simulated flights (83), public speaking (84), race car
rivers (85), and so on, and are also efficacious in the treatment
f supraventricular arrhythmias and effective in the control of
entricular arrhythmias related to sympathetic activation and
revents sudden cardiac death (86).
hysicians’ misperception of beta-blockers in the man-
gement of hypertension. Unfortunately, physicians still
erceive beta-blockers as exceedingly efficacious antihyper-
ensive drugs. In a recent survey (87) in which physicians
ere asked “Which of the following class of drugs have been
trength of Evidence for the Usef Beta-Blockers in Cardiovascular Disease
Table 2 Strength of Evidence for the Useof Beta-Blockers in Cardiovascular Disease
Conditions
Weak to
None
Some
Evidence
Strong
Evidence
Hypertension (uncomplicated) ✓
Heart failure ✓
Acute coronary syndrome ✓
Postmyocardial infarction ✓
Stable angina without MI ✓
Perioperative (noncardiac
surgery)
✓
HOCM ✓OCM  hypertropic obstructive cardiomyopathy; MI  myocardial infarction.
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Beta-Blockers in Cardiovascular Disease August 14, 2007:563–72roven to reduce the risk of stroke in hypertensive patients?”
eta-blockers were by far considered the most effective class.
imilarly, when asked, “Which of the following classes of
rugs have been proven to reduce mortality in hypertensive
atients?” beta-blockers were rated highest. These percep-
ions or misperceptions are unfortunate and obviously must
e considered as long-lasting repercussions of deceptive
arketing by the pharmaceutical industry that beta-blockers
ere “cardioprotective.”
onclusions
he strength of evidence supporting the use of beta-
lockers in certain cardiovascular conditions is summarized
n Table 2. In patients with uncomplicated hypertension,
here is paucity of data or absence of evidence to support use
f beta-blockers as monotherapy or as first-line agents.
iven the risk of stroke, lack of cardiovascular morbidity
nd mortality benefit, numerous adverse effects, lack of
egression of target end-organ effects of hypertension like
VH, and endothelial dysfunction, the risk benefit ratio for
eta-blockers is not acceptable for this indication. Guideline
ommittees should revise recommendations for beta-
lockers as first-line therapy for uncomplicated hyperten-
ion. It is worthwhile to note that the British Hypertension
ociety has withdrawn its endorsement of beta-blockers as
rst-line treatment for patients with uncomplicated hyper-
ension (88). In patients with uncontrolled or complicated
ypertension, beta-blockers can be considered in the arma-
entarium of treatment (Fig. 3).
However, it must be clearly emphasized that all outcomes
tudies showing no benefit in hypertension were conducted
ith traditional beta-blockers such as atenolol and metoprolol.
hether the newer vasodilating agents such as nebivolol and
arvedilol, which have a more favorable hemodynamic and
etabolic profile, will be more efficacious in reducing morbid-
ty and mortality, remains to be determined.
Beta-blockers, however, have been, are, and will remain the
ornerstone for the treatment of heart failure. For patients with
Figure 3 Proposed Use of Beta-Blockers for Hypertension
In patients with uncomplicated hypertension, beta-blockers should not be used
as first-line agents. However, in patients with uncontrolled hypertension on vari-
ous other antihypertensive agents and in those with complicated hypertension,
beta-blockers should be considered in the armamentarium of treatment. CHF 
chronic heart failure; MI  myocardial infarction.revious MI and hypertrophic obstructive cardiomyopathy,here is strong evidence to suggest its beneficial effects, pro-
ided patients can tolerate these medications. However, the
vidence supporting its use perioperatively for noncardiac
urgery is now been called into question.
At the time of writing this article, the AHA Council for
igh Blood Pressure Research and the European Society of
ypertension/European Society of Cardiology are no
onger endorsing beta-blockers as first-line treatment for
ncomplicated hypertension (89,90).
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